Belgium and the Netherlands deepen nuclear partnership with Tractebel-NRG Pallas deal.
It’s a quiet but steady revolution in the world of nuclear research. While political attention turns toward reactors powering entire cities, one small but mighty project in the Netherlands is quietly rewriting the future of medical isotopes, research irradiation, and nuclear know-how. On August 1, 2025, Tractebel and NRG-Pallas announced a renewed partnership to bring the long-awaited Pallas reactor in Petten closer to reality.
You can also read:
- Nuclear: a handshake in Washington that could power the future
- This Scandinavian startup wants to power the world with a nuclear reactor the size of a shipping container
A partnership forged in precision
For over a decade, Belgian engineering firm Tractebel, part of the Engie Group, has been embedded deep in the heart of the Pallas project. Since 2015, Tractebel—alongside its subcontractor NucAdvisor—has acted as Owner’s Engineer, overseeing technical safety, licensing, civil design, and project management.
This new agreement isn’t just a signature on a document. It’s a continuation of Tractebel’s active role in the reactor’s success, through the embedding of long-term experts into the integrated project team and continued involvement in civil engineering reviews and safety governance. One of Tractebel’s experts even chairs the Pallas Safety Committee.
According to Tractebel’s Dutch country manager, Deepak Narasimhamurthy, this partnership reflects a shared mission: “Healthcare, innovation, and energy security converge here. This renewed trust positions Tractebel as a long-term strategic partner in the Netherlands’ nuclear future.”
Why Pallas matters more than ever
The Pallas research reactor, now under construction in Petten, is not a power plant. It’s something even more delicate—and urgent. Pallas is set to replace the aging High Flux Reactor (HFR), operational since 1960 and responsible for 60% of Europe’s and 30% of the world’s supply of medical radioisotopes, including Molybdenum-99, essential for cancer diagnostics.
Pallas will use a tank-in-pool design, reach 55 MW thermal power, and optimize neutron flux like never before. That means more efficient production of medical isotopes, better research conditions for materials science, and a safer, more flexible infrastructure for the decades ahead.
A deep pit and deeper commitment
The groundwork—quite literally—has already been laid. In May 2023, Belgian firm Besix completed a 50-by-50-meter, 17.5-meter-deep construction pit for the new reactor. By May 2025, the foundation was finished. This phase alone involved some of the most complex civil engineering challenges in nuclear infrastructure today.
Tractebel has been active across every stage:
- Site selection and licensing, including nuclear documentation
- Design compliance reviews based on global safety standards
- Procurement risk analysis and mitigation strategies
- Construction oversight, especially for the reactor’s unique foundation design
In short: if there’s a trench, a weld, or a license involved, Tractebel has a hand in it.
Delays, green lights, and cautious optimism
Officially, Pallas received its construction license in February 2023 from the ANVS (Dutch nuclear safety authority). Yet political caution remains. Although €2 billion ($2.2 billion) in funding has been approved by the European Commission under state aid rules, the Dutch government has not yet given the final go-ahead for full construction.
In the meantime, former Minister Ernst Kuipers instructed NRG-Pallas to proceed with all preparatory steps without crossing any irreversible thresholds. As of July 2025, outgoing Health Minister Daniëlle Jansen confirmed to Parliament that the project is ready to move into its next phase.
Building knowledge, not just concrete
One of the most significant aspects of the new agreement is knowledge transfer. Tractebel is actively training NRG-Pallas staff, supporting the growth of what is called the “Intelligent Customer” and the “Design Authority” roles—essential for any modern nuclear operator.
This is more than box-ticking. It’s about ensuring that the organization understands its own design, can challenge vendors, and can operate independently and responsibly over the reactor’s full lifecycle.
Europe’s isotope lifeline, reborn
With the High Flux Reactor nearing the end of its lifespan, the Pallas reactor isn’t just a research tool. It’s a strategic asset for European healthcare, scientific independence, and supply chain resilience in a global market strained by geopolitical uncertainties.
While Pallas won’t be turning on lightbulbs, it might save lives—by enabling earlier cancer diagnoses, advancing nuclear medicine, and supporting material testing for advanced energy systems.
In the shadows of megaprojects and gigawatt headlines, Pallas stands as a reminder: sometimes, the most transformative energy doesn’t power cities. It powers discovery.
Better late than never: a forgotten 1938 experiment just reshaped nuclear fusion research
Pallas project at a glance
| Parameter | Detail |
| Location | Petten, Netherlands |
| Reactor Type | Tank-in-pool, 55 MW thermal |
| Purpose | Medical isotope production, irradiation research |
| Engineering Lead | Tractebel (Owner’s Engineer) |
| Construction Status | Foundation & pit completed (May 2025) |
| License Granted | February 2023 (ANVS) |
| EU State Aid Approved | €2 billion ($2.2 billion) |
| Site Characteristics | 50 m x 50 m x 17.5 m excavation |
| Reactor Replacing | High Flux Reactor (in operation since 1960) |
| Estimated Operational Role | 60% of Europe’s medical isotopes |
Source: Tractebel press release (Aug 1, 2025).
